GSK•benzinga•
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile
Summary
iTeos ends belrestotug program with GSK after Phase 2 trial fails to meet key survival goals; company explores strategic options to boost shareholder value.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 13, 2025 by benzinga